Peptides DB
Research-centric peptide and protocol reference hub
Study 5 of 41Erythropoietin (EPO) literatureeuropepmc · Observational2026

Erythropoietin receptor upregulation is associated with tubular injury severity in human acute kidney injury.

EPOR expression is significantly higher in acute kidney injury compared to controls and correlates with injury severity, but the clinical implications of these findings need further investigation.

Read at europepmcAdd to compare

Where it sits

this study against the rest of the erythropoietin (epo) corpus
6
Preclinical
26
Observational · this one
1
Open-label
2
Randomised
6
Reviews

Summary and findings

This study investigated erythropoietin receptor (EPOR) expression in human acute kidney injury (AKI) by analyzing renal biopsy specimens from 21 patients with AKI and 12 control samples. The findings indicated that EPOR expression was significantly higher in AKI kidneys compared to controls, with various correlations to injury severity. No therapeutic claims are made.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
EPOR expression was significantly higher in AKI kidneys compared to controls, p<0.001.2026

Abstract

The authors’ words, as europepmc supplied them

Objective This study aimed to investigate erythropoietin receptor (EPOR) expression in human AKI and to examine its association with histopathological severity and clinical parameters. Methods Renal biopsy specimens from 21 patients with biopsy-confirmed acute kidney injury (AKI) and 12 control kidney tissues from nephrectomy samples were analyzed. EPOR expression was assessed by immunohistochemistry with AI-assisted digital quantification and by immunofluorescence, including co-staining with β-common receptor (βcR) and TUNEL. Results In human kidney biopsy specimens, EPOR expression was significantly higher in AKI kidneys compared to controls (p < 0.001). Immunofluorescence demonstrated co-localization of EPOR and βcR on tubular epithelial cell membranes. EPOR expression showed significant inverse correlations with stage of AKI (τ = -0.444, p = 0.012), tubular necrosis scores (τ = -0.485, p = 0.005), and acute pathology scores (τ = -0.475, p = 0.005). A significant positive correlation was found between EPOR expression and both red blood cell count (r = 0.490, p = 0.024) and Hemoglobin levels (r = 0.496, p = 0.022). Receiver operating characteristic analysis indicated moderate discriminatory performance of EPOR expression for differentiating AKI severity stages. Consistent with the human data, EPOR protein levels were significantly upregulated in mouse kidneys 24 h after ischemia-reperfusion injury. Single-cell transcriptomic analysis further demonstrated increased EPOR expression in tubular cell populations in AKI. Conclusions EPOR expression is upregulated in renal tubular epithelial cells in human AKI and is closely associated with histopathological injury severity and selected clinical parameters, highlighting that EPOR may serve as a marker of tubular stress and injury severity in AKI.

Background

The paper addresses the role of erythropoietin receptors in acute kidney injury (AKI), a condition characterized by rapid loss of kidney function. Prior research has indicated that erythropoietin may have protective effects in kidney injury, but the relationship between receptor expression and injury severity remains unclear. Understanding this relationship is crucial for developing potential therapeutic strategies.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Key findings

  • Not reported in abstract.

Limitations

  • Not reported in abstract.

Elsewhere in the Erythropoietin (EPO) corpus

DErythropoietin beyond red blood cells: Systemic and oncological functions (Review).Molecular medicine reports · 2026reviewDSodium-Glucose Cotransporter 2 Inhibitor Use and Levels of Hemoglobin, Markers of Iron Metabolism, and Erythropoiesis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.JAMA · 2026 · Hemoglobin changed by 0.55 g/dL in the SGLT2 inhibitor group, P<0.001.reviewBResponsiveness to Erythropoiesis‑Stimulating Agents and Hemoglobin Variability in Japanese Patients With End‑Stage Kidney Diseasebiorxiv-preprint · 2026 · ERI was positively correlated with Hb-RSD (r = 0.473, p = 0.003).HumanBBlood Free Carnitine Level is an Independent Determinant of Erythrocyte Membrane Homogeneity and Osmotic Resistance in Maintenance Hemodialysis Patientsbiorxiv-preprint · 2026 · Higher FC levels were associated with increased OFT slope a (β=0.6090, P=0.036).HumanBGenetic mimicry of haematopoietic growth factor signalling: efficacy–safety trade-offs for cytopenias by drug-target Mendelian randomisationbiorxiv-preprint · 2026 · OR 0.65, 95% CI 0.49–0.86, P=0.0026 for lower thrombocytopenia risk with higher MPL expression.HumanCIn vivo HSPC gene therapy of hemoglobinopathies without drug selection of corrected cellsbiorxiv-preprint · 2026 · >70% HbF-positive erythroid cells in treated miceAnimal